PPIDT00430
Drug Information
| Name | Crizanlizumab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB15271 |
| Type | biotech |
| Indication | Crizanlizumab is indicated to reduce the frequency of vaso-occlusive crisis in patients with sickle cell diseases who are ≥16 years old.[L10097] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Intravenous |
10 mg/1mL
|
| Injection, solution, concentrate | Intravenous |
10 MG/ML
|